BiotechTV - News - TopPodcast.com

Latest Episodes:

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on ACM, and more Apr 23, 2025

Show notes

He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a clinical trial for accelerated approval by early 2026. Plus, how we should expect more ACM data in 2025.

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides Apr 23, 2025

Show notes

He describes how Metsera, which had its IPO two months ago, is aiming to develop a differentiated GLP-1 vs currently marketed products by having a lower dose and longer half-life. We discuss all the hot button issues in the obesity space today.

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73 Apr 17, 2025

Show notes

He describes the market potential of the company's HIF-2⍺, a target that has already been de-risked by a large pharma, why he believes being Fc silent will allow Arcus to succeed in TIGIT where others have failed, and a CD73 program that is enrolling very quickly in pancreatic cancer.

As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact Apr 16, 2025

Show notes

CSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research circles. Plus, his take on what regulatory reforms could help U.S. competitiveness, and areas of research that excite him today.

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies Apr 16, 2025

Show notes

Founder and CEO Nicole Paulk describes the process, which allows the public to invest as little as $100, and why she views the investors that come with it as an asset for her company.

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA) Apr 15, 2025

Show notes

CEO Rick Winningham describes the science behind ampreloxetine, and the rationale for developing it for patients with multiple system atrophy. A commercial stage company that already receives income from two therapies (YUPELRI and TRELEGY), Theravance Biopharma's future direction and focus will be determined by the outcome of this key trial.

Marea Therapeutics today announced acceptance of a late-breaker at #EASCongress2025 for its ANGPTL4 inhibitor - believed to be the first ever clinical data presented for this lipid lowering target Apr 15, 2025

Show notes

CEO Josh Lehrer and CSO Ethan Weiss describe the biology of the target and highlight the topline data, which was first announced at #JPM25. Plus, details on a new program targeting acromegaly.

After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor Apr 14, 2025

Show notes

Co-Founder & CEO Sek Kathiresan walks us through the data, which so far has showed a clean safety profile and an impressive ability to lower LDL by over 50% in patients with a genetic form of hypercholesterolemia.

Mount Sinai has embraced AI as a drug discovery tool by launching this month its new AI Small Molecule Drug Discovery Center - Professor Avner Schlessinger tells us why Apr 10, 2025

Show notes

Dr. Schlessinger descrbies how the new center is meant to speed up drug discovery work and enable Mount Sinai researchers to develop molecules that are more dynamic and with a higher success rate. It might also enable them to take drug development further than they traditionally have before.

Jones Healthcare & Technology Innovation Conference: Jones Research analysts Soumit Roy and Justin Walsh share their take on biotech and comment on companies they cover Apr 10, 2025

Show notes

They discusses takeaways from the conference, and comment on Beam, Korro, Wave, Intellia, Prime, Janux, Alto Nuero, Rapport, and YmAbs.

Our TOPPODCAST Picks

Follow Us

Stay Connected

BiotechTV – News

Related Podcasts

Links

Stay Connected